C. Cilibrasi, V. Butta, G. Riva, and A. Bentivegna, “Pioglitazone Effect on Glioma Stem Cell Lines: Really a Promising Drug Therapy for Glioblastoma?,” PPAR Research, vol. 2016 (2016). https://doi.org/10.1155/2016/7175067.
In the article titled “Pioglitazone Effect on Glioma Stem Cell Lines: Really a Promising Drug Therapy for Glioblastoma?,” there was an error in Figure 5. Specifically, an incorrect image was selected for the cells in the control group stained for CD133/IP/Ph as it represents untreated GliNS2 cells stained for CD133 as reported in a previous publication by the same author group [1]. The error was introduced by the authors during figure assembly and Figure 5 should be corrected as follows:
Figure 5.
Selected representative images of immunofluorescence assays for stemness and differentiation markers. Immunofluorescence assays were performed on untreated (ctrl) and 10 µM Pio‐treated GSCs for 72 h. Each specific maker is in green; phalloidin is in blue and propidium iodide in red.
We apologize for these errors.
References
- 1. Riva G., Baronchelli S., Paoletta L., Butta V., Biunno I., Lavitrano M., Dalprà L., and Bentivegna A., In Vitro Anticancer Drug Test: A New Method Emerges From the Model of Glioma Stem Cells, Toxicology Reports. (2014) 1, 188–199, 10.1016/j.toxrep.2014.05.005, 28962238. [DOI] [PMC free article] [PubMed] [Google Scholar]